(Q37738472)

22 August 2017

1 reference

title

New approaches for the detection of minimal residual disease in acute myeloid leukemia (English)

1 reference

22 August 2017

1 reference

Anna van Rhenen

1

1 reference

22 August 2017

Bijan Moshaver

series ordinal

2

1 reference

22 August 2017

Gert J Ossenkoppele

series ordinal

3

1 reference

22 August 2017

Gerrit Jan Schuurhuis

series ordinal

4

1 reference

22 August 2017

publication date

1 May 2007

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

111-118

1 reference

8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity

22 August 2017

cites work

1 reference

12 December 2020

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia

1 reference

12 December 2020

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

12 December 2020

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

1 reference

12 December 2020

Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species.

1 reference

12 December 2020

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

12 December 2020

Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.

1 reference

12 December 2020

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

1 reference

12 December 2020

A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia

1 reference

12 December 2020

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

12 December 2020

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

1 reference

12 December 2020

Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now

1 reference

12 December 2020

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

1 reference

12 December 2020

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis

1 reference

12 December 2020

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

12 December 2020

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.

1 reference

12 December 2020

Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities

1 reference

12 December 2020

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

1 reference

12 December 2020

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Acute myeloid leukemia and acute promyelocytic leukemia.

1 reference

12 December 2020

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

1 reference

12 December 2020

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

12 December 2020

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia

1 reference

12 December 2020

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

1 reference

12 December 2020

Minimal residual disease studies in acute leukemia

1 reference

12 December 2020

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

1 reference

12 December 2020

Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias

1 reference

12 December 2020

Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia

1 reference

12 December 2020

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

12 December 2020

Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

1 reference

12 December 2020

Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.

1 reference

12 December 2020

A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.

1 reference

12 December 2020

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

12 December 2020

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

1 reference

12 December 2020

Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.

1 reference

12 December 2020

Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.

1 reference

12 December 2020

Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study

1 reference

12 December 2020

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

1 reference

12 December 2020

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

1 reference

12 December 2020

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia

1 reference

12 December 2020

PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects

1 reference

12 December 2020

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

1 reference

12 December 2020

Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL

1 reference

12 December 2020

Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

1 reference

12 December 2020

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1 reference

12 December 2020

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).

1 reference

12 December 2020

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

1 reference

12 December 2020

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

1 reference

12 December 2020

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

12 December 2020

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

1 reference

12 December 2020

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

1 reference

12 December 2020

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

12 December 2020

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

12 December 2020

10.1007/S11899-007-0016-0

Identifiers

DOI

1 reference

22 August 2017

1 reference